Patents by Inventor Hiroo Iwata

Hiroo Iwata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220372419
    Abstract: An aspect of the present invention makes it possible to easily observe both surfaces of a cell sheet in a condition in which the cell sheet is at a stable position in a culture medium. A cell sheet production device (100) includes: a container (20); and a support unit (10) removably held in the container (20), the support unit (10) including a mesh sheet (2) and a base (3) which holds the mesh sheet (2) such that the mesh sheet (2) floats from a bottom surface of the container (20), the support unit (10) being held in the container (20) such that the support unit is at a fixed position in vertical and horizontal directions in a culture medium.
    Type: Application
    Filed: October 15, 2020
    Publication date: November 24, 2022
    Inventors: Takeshi HORI, Hiroo IWATA, Osamu KUROSAWA, Nobutaka TANI, Taro MIZUTA, Kouhei ISHIHARA
  • Patent number: 11345986
    Abstract: The present invention provides an alloy for medical use including an Au—Pt alloy, in which the Au—Pt alloy has a Pt concentration of 24 mass % or more and less than 34 mass % with the balance being Au, and has at least a material structure in which a Pt-rich phase having a Pt concentration higher than that of an ?-phase is distributed in an ?-phase matrix, the Pt-rich phase has a Pt concentration that is 1.2 to 3.8 times the Pt concentration of the ?-phase, and the Pt-rich phase has an area ratio of 1 to 22% in any cross-section. This alloy is an artifact-free alloy material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to magnetic susceptibility of water.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 31, 2022
    Assignees: TANAKA KIKINZOKU KOGYO K.K., KYOTO UNIVERSITY
    Inventors: Kunihiro Shima, Kenji Goto, Yasushi Masahiro, Asaka Ueno, Hiroo Iwata, Ryusuke Nakai, Tomonobu Kodama
  • Patent number: 11291798
    Abstract: A vascular embolization device includes a coil with a primary shape and an stretch resistant wire provided inside the coil, in which the stretch resistant wire is a multilayer strand including at least one core layer and at least one outer layer including one or more resin compositions and a biochemical active material, and the core layer is composed of a material with a tensile break strength higher than that of the outer layer. The vascular embolization device has the function of administering a biochemical active material and also has good flexibility.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 5, 2022
    Assignee: KANEKA MEDIX CORPORATION
    Inventors: Hitoshi Ozasa, Atsushi Ogawa, Yasushi Yamanaka, Hiroo Iwata, Tomonobu Kodama
  • Publication number: 20210047717
    Abstract: The present invention provides an alloy for medical use including an Au—Pt alloy, in which the Au—Pt alloy has a Pt concentration of 24 mass % or more and less than 34 mass % with the balance being Au, and has at least a material structure in which a Pt-rich phase having a Pt concentration higher than that of an ?-phase is distributed in an ?-phase matrix, the Pt-rich phase has a Pt concentration that is 1.2 to 3.8 times the Pt concentration of the ?-phase, and the Pt-rich phase has an area ratio of 1 to 22% in any cross-section. This alloy is an artifact-free alloy material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to magnetic susceptibility of water.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 18, 2021
    Inventors: KUNIHIRO SHIMA, KENJI GOTO, YASUSHI MASAHIRO, ASAKA UENO, HIROO IWATA, RYUSUKE NAKAI, TOMONOBU KODAMA
  • Patent number: 10883162
    Abstract: The present invention provides an alloy for medical use including an Au—Pt alloy, in which the Au—Pt alloy has a Pt concentration of 24 mass % or more and less than 34 mass % with the balance being Au, and has at least a material structure in which a Pt-rich phase having a Pt concentration higher than that of an ?-phase is distributed in an ?-phase matrix, the Pt-rich phase has a Pt concentration that is 1.2 to 3.8 times the Pt concentration of the ?-phase, and the Pt-rich phase has an area ratio of 1 to 22% in any cross-section. This alloy is an artifact-free alloy material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to magnetic susceptibility of water.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 5, 2021
    Assignees: TANAKA KIKINZOKU KOGYO K.K., KYOTO UNIVERSITY
    Inventors: Kunihiro Shima, Kenji Goto, Yasushi Masahiro, Asaka Ueno, Hiroo Iwata, Ryusuke Nakai, Tomonobu Kodama
  • Publication number: 20200208093
    Abstract: As a cell-encapsulating device that may supply sufficient oxygen to cells in an implant part and therefore encapsulate a larger cell aggregate, there is provided a cell-encapsulating device comprising a plurality of capsule-form structures arrayed in two-dimensional directions in the same plane, wherein at least a part of outer shells of the capsule-form structures is formed from an oxygen-permeable membrane, and cells are encapsulated in the inside of the capsule-form structures.
    Type: Application
    Filed: June 13, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Hiroo Iwata
  • Publication number: 20190136197
    Abstract: Disclosed are a method for culturing pancreatic progenitor cells derived from pluripotent stem cells, the method comprising step (A) of three-dimensionally culturing pancreatic progenitor cells derived from pluripotent stem cells in a medium containing a factor belonging to the epidermal growth factor (EGF) family and/or a factor belonging to the fibroblast growth factor (FGF) family, and (2) a Wnt agonist; a method for producing islet cells from pancreatic progenitor cells derived from pluripotent stem cells, the method comprising step (E) of inducing the differentiation of pancreatic progenitor cells cultured by the above method into islet cells; and a method for cryopreserving pancreatic progenitor cells derived from pluripotent stem cells, the method comprising step (F) of freezing pancreatic progenitor cells cultured by the above method.
    Type: Application
    Filed: April 27, 2017
    Publication date: May 9, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroo IWATA, Shuhei KONAGATA
  • Patent number: 10238714
    Abstract: A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 26, 2019
    Assignees: KYOTO UNIVERSITY, ARKRAY, Inc., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Hiroo Iwata, Rei Kuwabara, Masahide Hamaguchi, Kunio Hirano, Shimon Sakaguchi
  • Patent number: 10220120
    Abstract: The present invention is an alloy for medical use including an Au—Pt alloy, containing 34 to 36 mass % of Pt with the balance being Au, and having an ?-phase single structure in which a ratio of a peak intensity (X) of a Pt (111) plane to a peak intensity (Y) of an Au (111) plane (X/Y) is 0.01 or less in an X-ray diffraction analysis. The alloy can be produced in such a manner that after the Au—Pt alloy ingot is molten and cast, cold working and a heat treatment for homogenization are performed at least two times on the molten and cast alloy. The alloy of the present invention is an artifact-free material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to that of water.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 5, 2019
    Assignees: TANAKA KIKINZOKU KOGYO K.K., KYOTO UNIVERSITY
    Inventors: Kunihiro Shima, Kenji Goto, Yasushi Masahiro, Asaka Ueno, Hiroo Iwata, Ryusuke Nakai, Tomonobu Kodama
  • Publication number: 20180036508
    Abstract: A vascular embolization device includes a coil with a primary shape and an stretch resistant wire provided inside the coil, in which the stretch resistant wire is a multilayer strand including at least one core layer and at least one outer layer including one or more resin compositions and a biochemical active material, and the core layer is composed of a material with a tensile break strength higher than that of the outer layer. The vascular embolization device has the function of administering a biochemical active material and also has good flexibility.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 8, 2018
    Applicant: KANEKA MEDIX CORPORATION
    Inventors: Hitoshi OZASA, Atsushi OGAWA, Yasushi YAMANAKA, Hiroo IWATA, Tomonobu KODAMA
  • Publication number: 20180028190
    Abstract: A vascular embolization device having the function of administering a biochemical active material and also having high flexibility is provided. Specifically, the vascular embolization device includes a coil and a biochemical active material-containing resin wire inserted in the inside of the coil, in which the resin wire is a multilayer strand including a core and at least one outer layer, and the core and the at least one outer layer individually include resin compositions with solubilities different from each other in the same organic solvent.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 1, 2018
    Applicant: KANEKA MEDIX CORPORATION
    Inventors: Hitoshi OZASA, Atsushi OGAWA, Yasushi YAMANAKA, Hiroo IWATA, Tomonobu KODAMA
  • Publication number: 20170029927
    Abstract: The present invention provides an alloy for medical use including an Au—Pt alloy, in which the Au—Pt alloy has a Pt concentration of 24 mass % or more and less than 34 mass % with the balance being Au, and has at least a material structure in which a Pt-rich phase having a Pt concentration higher than that of an ?-phase is distributed in an ?-phase matrix, the Pt-rich phase has a Pt concentration that is 1.2 to 3.8 times the Pt concentration of the ?-phase, and the Pt-rich phase has an area ratio of 1 to 22% in any cross-section. This alloy is an artifact-free alloy material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to magnetic susceptibility of water.
    Type: Application
    Filed: January 30, 2014
    Publication date: February 2, 2017
    Applicants: TANAKA KIKINZOKU KOGYO K.K., KYOTO UNIVERSITY
    Inventors: Kunihiro SHIMA, Kenji GOTO, Yasushi MASAHIRO, Asaka UENO, Hiroo IWATA, Ryusuke NAKAI, Tomonobu KODAMA
  • Publication number: 20160367729
    Abstract: The present invention is an alloy for medical use including an Au—Pt alloy, containing 34 to 36 mass % of Pt with the balance being Au, and having an ?-phase single structure in which a ratio of a peak intensity (X) of a Pt (111) plane to a peak intensity (Y) of an Au (111) plane (X/Y) is 0.01 or less in an X-ray diffraction analysis. The alloy can be produced in such a manner that after the Au—Pt alloy ingot is molten and cast, cold working and a heat treatment for homogenization are performed at least two times on the molten and cast alloy. The alloy of the present invention is an artifact-free material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of ±4 ppm with respect to that of water.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 22, 2016
    Inventors: Kunihiro SHIMA, Kenji GOTO, Yasushi MASAHIRO, Asaka UENO, Hiroo IWATA, Ryusuke NAKAI, Tomonobu KODAMA
  • Publication number: 20160303188
    Abstract: A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 20, 2016
    Inventors: Hiroo Iwata, Rei Kuwabara, Masahide Hamaguchi, Kunio Hirano, Shimon Sakaguchi
  • Publication number: 20160304839
    Abstract: Provided is a method for producing a pseudoislet, which method comprises: seeding 1,500 to 5,000 pluripotent stem cells in a cell culture well to prepare an aggregate of said pluripotent stem cells, said aggregate having a predetermined size; and culturing said aggregate in said cell culture well in a nonadherent state, to allow differentiation into cells including pancreatic islet progenitor cells and/or pancreatic islet cells.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Hiroo Iwata, Shuhei Konagaya, Kunio Hirano
  • Publication number: 20160228473
    Abstract: The present invention provides a device to be implanted subcutaneously for forming a transplantation space where rejection does not occur, wherein the device comprises a biocompatible structure containing an angiogenesis inducing factor.
    Type: Application
    Filed: September 19, 2014
    Publication date: August 11, 2016
    Inventors: Hiroo Iwata, Nguyen Minh Luan
  • Publication number: 20160120932
    Abstract: A method of forming a transplant site, the method comprising a process of contacting SEK-1005 (Ser,3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) with a body tissue.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Inventors: Hiroo Iwata, Rei Kuwabara, Kunio Hirano
  • Patent number: 9040111
    Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 26, 2015
    Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 8968392
    Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: March 3, 2015
    Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 8641756
    Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 4, 2014
    Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata Institute for Frontier Medical Sciences, Kyoto University
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki